Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential

1

Autoantibodies can serve as immunodiagnostic markers for early cancer diagnosis, detectable before clinical symptoms appear.
2

Tumor-associated autoantibodies (TAAbs) are stable in plasma and persist longer than conventional tumor markers, aiding in diagnosis and treatment.
3

Detection methods for TAAbs include protein chips, immunofluorescence assays, and ELISA, offering high sensitivity and cost-effectiveness.
4

TAAbs show potential as non-invasive biomarkers for distinguishing between benign and malignant tumors and may indicate prognosis.
5

The mechanisms behind TAAbs involve immune system dysregulation and tumor microenvironment factors, linking autoimmunity and malignancy.

1